Oestrogen/progesterone receptors and a 65 kD tumour-associated phosphoprotein (p65) expression in breast cancer patients

Biomedical Letters

Volumn 56, Issue 222, 1997, Pages 91-99

  Niewiadomska, H ^a   Mirowski, M ^a,c   Bartkowiak, J ^a   Stempien, M ^e   Blonski, J Z ^e   Walaszek, Z ^b,d   Hanausek, M ^b   Wierzbicki, R ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF TEXAS   (United States)

^c SOLTAN INSTITUTE FOR NUCLEAR STUDIES   (Poland)

^d Biomedical Horizons Institute   (United States)

^e NONE

Author keywords

Anti p65 antibody; Breast cancer; Oestrogen and progesterone receptor; Oncofoetal protein

Indexed keywords

EID: 0041195095     PISSN: 0961088X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. BEATO M. 1989. Gene regulation by steroid hormones. Cell 56 335-44.
2. BILIMORIA M. M. and Morrow M. 1995. The women at increased risk for breast cancer: evaluation and management strategies. CA Cancer J. Clin. 45 263-78.
3. BLOOM H. J. G. and Richardson W. W. 1957. Histological grading and prognosis in breast cancer. A study of 1,409 cases of which 359 have been followed for 15 years. Br. J. Cancer 11 359-77.
4. CARSON-JURICA M. A., Schrader W. T. and O'Malley B. W. 1990. Steroid receptor family: structure and function. Endocr. Rev. 11 201-19.
5. DISTEFANO D., Mingazzini P. L., Scucchi L., Donnetti M. and Marinozzi V. 1991. A comparative study of histopathology, hormone receptors, peanut lectin binding, Ki67 immunostaining and nucleolar organizer region-associated proteins in human breast cancer. Cancer 67 463-71.
6. DZIEWULSKA-BOKINIEC A., Ciesieslki D., Kopacz A., Roszkiewicz A. and Kruszewska E. 1992. Oestrogen receptor level as a function of histological grading of the tumour in patients suffering from breast cancer. (In Polish). Ginekologia Pol. 63 304-7.
7. EVANS R. M. 1988. The steroid and thyroid hormone receptor superfamily. Science 240 889-95.
8. GARCIA M., Derocq D., Freiss G. and Rochefort H. 1992. Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells. Proc. natn. Acad. Sci. U.S.A. 89 11538-42.
9. GLASS C. K., Holloway J. M., Devary O V. and Rosenfeld M. G. 1988. The thyroid hormone receptor binds with opposite transcriptional effects to a common sequence motif in thyroid hormone and estrogen response elements. Cell 54 313-23.
10. GOTELLAND M., May E., May-Levin F., Contesso G., Delarue J. C. and Mouriesse H. 1994. Estrogen receptors (ER) in human breast cancer. The significance of a new prognostic factor based on both ER protein and ER mRNA contents. Cancer 74 864-71.
11. HANAUSEK M., Szemraj J., Adams A. K. and Walaszek Z. 1996. The oncofetal protein p65: a new member of the steroid/thyroid receptor superfamily. Cancer Detect. Prevent. 20 94-102.
12. HORWITZ K. B. 1993. Mechanisms of hormone resistance in breast cancer. Breast Cancer Res. Treat. 26 119-30.
13. HSU S. M., Raine L. and Fanger H. 1981. Jse of avidin-biotin-peroxidase complex (ABC) inmmunoperoxidase techiques: a comparison between ABC and unlabelled antibody PAP procedures. J. Histochem. Cytochem. 29 577-80.
14. MANSOUR E. G., Ravdin P. M. and Dressler L. 1994. Prognostic factors in early breast carcinoma. Cancer 74 381-400.
15. MIROWSKI M., Bloński J. Z., Niewiadomska H., Olborski B., Walaszek Z., Hanausek M. and Wozniak L. 1997. Immunohistochemical study of 65-kDa oncofetal protein expression in breast cancer. Breast In press.
16. MIROWSKI M., Walaszek Z., Sherman U. and Hanausek M. 1993. Comparative structural analysis of human and rat p65kD tumor-associated phosphoproteins. Int. J. Biochem. 25 1865-71.
17. MIROWSKI M., Walaszek Z. and Hanausek M. 1996. Presence in bovine fetal serum of the protein antigenically related to p65-tumor associated antigen: its isolation and polyclonal antibody production. Neoplasma 43 83-8.
18. NIEWIADOMSKA H., Mirowski M., Stempien M., Bloński J. Z. and Hanausek M. 1996. Clinical evaluation of the usefulness of polyclonal and monoclonal antibodies raised against p65 protein in immunohistochemical diagnosis of breast cancer: a comparative study. Biomedical Letters 54 223-31.
19. NOLTENIUS H. 1988. Human Oncology. Pathology and clinical characteristics. Vol 3, pp 903-95. Urban-Schwarzenberg, Baltimore.
20. PUJOL P., Hilsenbesk S. G., Chamness G C. and Elledge R. M. 1994. Rising levels of estrogen receptor in breast cancer over two decades. Cancer 74 1601-6.
21. WANG S., Mirowski M., Sherman U., Walaszek Z. and Hanausek M. 1993. Monoclonal antibodies against a 65-kDa tumor-associated phosphoprotein: development and use in cancer detection. Hybridoma 12 167-76.
22. YOO K. Y., Tajima K., Miura S., Yoshida VI., Murai H., Kuroishi T., Lee Y., Rish H. and Dubrov R. 1993. A hospital-based case-control study of breast cancer risk factors by estrogen and progesterone receptor status. Cancer Causes Control 4 39-44.